Compare LOW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOW | GILD |
|---|---|---|
| Founded | 1946 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2B | 173.9B |
| IPO Year | 1994 | 2001 |
| Metric | LOW | GILD |
|---|---|---|
| Price | $252.32 | $137.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 18 |
| Target Price | ★ $290.23 | $148.39 |
| AVG Volume (30 Days) | 2.0M | ★ 4.7M |
| Earning Date | 05-20-2026 | 04-24-2026 |
| Dividend Yield | 1.98% | ★ 2.37% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ 11.85 | 6.78 |
| Revenue | ★ $86,286,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $9.16 | $4.68 |
| Revenue Next Year | $3.56 | $6.04 |
| P/E Ratio | $20.46 | ★ $20.43 |
| Revenue Growth | 3.12 | ★ 9.98 |
| 52 Week Low | $210.33 | $95.30 |
| 52 Week High | $293.06 | $157.29 |
| Indicator | LOW | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 42.75 |
| Support Level | $240.13 | $133.89 |
| Resistance Level | $278.17 | $142.33 |
| Average True Range (ATR) | 5.83 | 3.25 |
| MACD | 2.45 | 0.09 |
| Stochastic Oscillator | 87.35 | 41.30 |
Lowe's is the second-largest home improvement retailer globally, with more than 1,750 stores in the US, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two-thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales) and do-it-for-me customers, but has expanded its professional business clients to 30% from less than 20% in the past six years (set ot expand further with the acquisition of FBM). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).